Incannex | Global leaders in cannabinoid & psychedelic therapies.

Our mission is to alleviate human suffering by creating novel, ethical drugs and therapies for patients with unmet medical needs, utilising compounds and delivery systems with strong pre-existing scientific signals of efficacy.

28 R&D programs and 6 clinical trials, with 1 primary goal – alleviate human suffering.

Clinical Development Pathway

Incannex is a medicinal cannabinoid and psychedelic therapy development company undertaking phase 2 clinical trials guided by its extended team, post liaison with FDA. With a diverse portfolio of 28 distinct research and development programs, 6 clinical trials underway and more planned, our programs target conditions for patients with unmet medical needs. This means we have an opportunity to treat a significant number of people – the potential is limitless.

Development Program

Pre-Discovery

Discovery

Pre-Clinical

Phase 1

Phase 2A

Phase 2B

Phase 3

IHL – 42X – OSA IHL-42X is a novel cannabinoid combination product for treatment of Obstructive Sleep Apnoea (OSA).

77%

PSI-GAD Incannex are developing a psilocybin assisted psychotherapy system for treatment of Generalised Anxiety Disorder (GAD).

70%

IHL-675A Lung Inflammation IHL-675A is a novel cannabinoid combination product for treatment of inflammatory diseases including inflammatory lung diseases such as COPD, asthma and ARDS.

64%

IHL-675A Rheumatoid Arthritis IHL-675A is a novel cannabinoid combination product for treatment of inflammatory diseases including rheumatoid arthritis.

64%

IHL-675A Inflammatory Bowel Disease IHL-675A is a novel cannabinoid combination product for treatment of inflammatory diseases including inflammatory bowel disease.

64%

IHL-216A TBI IHL-216A is a novel cannabinoid combination product for treatment of Traumatic Brain Injury (TBI).

52%

US$400B market potential.

The combined global market size of medical conditions we target exceeds US$400B per annum. This potential addressable market is calculated by combining the treatment markets of OSA, TBI, concussion, rheumatoid arthritis, inflammatory bowel disease, inflammatory lung conditions (ARDS, COPD, Asthma, Bronchitis) and generalised anxiety disorder (GAD). Success in the clinical development programmes will not only provide benefit to patients, but also offer significant economic potential for our shareholders.